{"result": "(\"entity\"<|>TORRES VELA E<|>PERSON<|>Torres Vela E is an author of the Manual de Endocrinología y Nutrición, which discusses hyperprolactinemia and its management.)\n##\n(\"entity\"<|>LÓPEZ MEZQUITA TORRES E<|>PERSON<|>López Mezquita Torres E is a co-author of the Manual de Endocrinología y Nutrición, contributing to the discussion on hyperprolactinemia.)\n##\n(\"entity\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Manual de Endocrinología y Nutrición is a comprehensive guide published by the Sociedad Española de Endocrinología y Nutrición, covering various endocrine disorders including hyperprolactinemia.)\n##\n(\"entity\"<|>HIPÓFISIS<|>GEO<|>The hypophysis, or pituitary gland, is a crucial gland in the endocrine system that regulates various hormones, including those related to prolactin.)\n##\n(\"entity\"<|>PROLACTINOMA<|>EVENT<|>Prolactinoma is a type of tumor that produces excess prolactin, leading to hyperprolactinemia, and is discussed in the context of treatment and management in the manual.)\n##\n(\"relationship\"<|>TORRES VELA E<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Torres Vela E is an author of the Manual de Endocrinología y Nutrición, contributing to the knowledge on hyperprolactinemia<|>8)\n##\n(\"relationship\"<|>LÓPEZ MEZQUITA TORRES E<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>López Mezquita Torres E is a co-author of the Manual de Endocrinología y Nutrición, contributing to the knowledge on hyperprolactinemia<|>8)\n##\n(\"relationship\"<|>HIPÓFISIS<|>PROLACTINOMA<|>The hypophysis is involved in the production of prolactin, which is related to the condition of prolactinoma<|>7)\n##\n(\"relationship\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>PROLACTINOMA<|>The Manual de Endocrinología y Nutrición discusses prolactinoma and its management<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: respuesta A correcta).\n        gonadotropinas y disminución de la esteroidogénesis adrenal (hipogonadismo hipogona-                                                              •  Apoplejía hipofisaria con síntomas neurológicos.\n        dotropo) (respuesta A).                                                                                                                           •  Deseo quirúrgico del paciente por intolerancia a agonistas dopaminérgicos o para re-\n        Cuando la causa de la hiperprolactinemia es un prolactinoma, tenemos que tener en cuenta                                                             ducir masa tumoral pregestación.\n        que existen diferencias epidemiológicas entre hombres y mujeres. La prevalencia general del                                                       •  Crecimiento tumoral durante la gestación que no responde a la reinstauración de tra-\n        prolactinoma es mayor en mujeres que en varones entre los 20 y 50 años, pero a partir de los                                                         tamiento con agonistas dopaminérgicos.\n        50 años es igual en ambos sexos. Sin embargo, las diferencias entre géneros se dan a expen-\n        sas de los microprolactinomas (mucho más frecuentes en mujeres que en varones), mientras                                                        Por tanto, no hay ninguna indicación quirúrgica que dependa únicamente del tamaño tumo-\n        que en los macroprolactinomas la frecuencia es similar en ambos sexos (opción C falsa).                                                         ral, la extensión extraselar y/o la invasión de senos cavernosos (respuestas B y C falsas).\n        Referencias:                                                                                                                                    Referencias:\n        • Torres Vela E, López Mezquita Torres E. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de Endocrinolo-            • Torres Vela E, López Mezquita Torres E. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de Endocrinolo-\n          gía y Nutrición; 2015. Capítulo 12. Hiperprolactinemias [citado 29 de abril de 2019]. Disponible en: https://manual.seen.es/article?id=-        gía y Nutrición; 2015. Capítulo 12. Hiperprolactinemias [citado 29 de abril de 2019]. Disponible en: https://manual.seen.es/article?id=-\n          55114b5e-a308-47b0-89af-2bcdac18103c.                                                                                                           55114b5e-a308-47b0-89af-2bcdac18103c.\n\n\n\n40                                                                                                                                                                                                                                                                                 41\n---\n                                                                                                                                                                                                                                           HIPÓFISIS                         1\n\n\n\n    30  ¿En cuál de las siguientes condiciones clínicas no suspendería usted el tratamiento                                                           COMENTARIO\n        con cabergolina después de 2 años de tratamiento y control clínico de la                                                                      La lactancia puede aumentar las concentraciones séricas de PRL, pero no parece aumentar el\n        hiperprolactinemia?                                                                                                                           riesgo de crecimiento del adenoma lactotropo. Por tanto, las mujeres con micro- y macroade-\n        A. Invasión de senos cavernosos.                                                                                                              nomas estables durante la gestación pueden plantearse lactar (respuesta B correcta).\n        B. Tamaño tumoral superior a 1 cm.                                                                                                            El tratamiento con agonistas dopaminérgicos no se debe mantener o reiniciar en la lactan-\n        C. Imposibilidad de realizar seguimiento clínico adecuado.                                                                                    cia, puesto que al disminuir los niveles de PRL inhibiría la producción de leche (respuestas\n        D.  En ninguna de las anteriores suspendería el tratamiento.                                                                                  C y D incorrectas).\n                                                                                                                                                        Contraindicación para la lactancia en prolactinomas: la lactancia estaría contraindi-\n                                                                                                                                                        cada en mujeres con deterioro visual tras el parto, porque en estos casos sí se requerirá\n        COMENTARIO                                                                                                                                      tratamiento con agonistas dopaminérgicos.\n        El tratamiento de los prolactinomas con agonistas dopaminérgicos es muy efectivo y en                                                         Referencias:\n        algunos casos logra la remisión de la hiperprolactinemia a largo plazo. Sin embargo, la                                                       • Snyder PJ. Management of lactotroph adenoma (prolactinoma) during pregnancy. En: Cooper DS, Lockwood CJ, Martin KA, eds.\n        suspensión del tratamiento puede producir recurrencia en la hiperprolactinemia y recreci-                                                       UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso el 29 de abril de 2019).\n        miento tumoral.\n          La suspensión de agonistas dopaminérgicos en el prolactinoma estaría indicada si, tras 2                                                32  Respecto a las causas farmacológicas de hiperprolactinemia, señale\n          años de tratamiento, el paciente mantiene normoprolactinemia y el tumor ha desaparecido.                                                    la afirmación incorrecta:\n        En caso de persistir restos tumorales no es aconsejable suspender el tratamiento por el                                                       A. El ipilimumab provoca hiperprolactinemia porque antagoniza el receptor D2 de la\n        elevado riesgo\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}